8-K: Ocean Biomedical Secures $450,000 Investment via Preferred Stock Offering to Fund Reverse Stock Split

Ocean Biomedical, Inc. announces a private placement of Series A redeemable convertible preferred stock to raise up to $450,000, primarily aimed at facilitating a reverse stock split.

Summary

• Ocean Biomedical, Inc. has entered into a securities purchase agreement on February 21, 2025, for a private placement of up to 45,000 shares of Series A redeemable convertible preferred stock.
• The purchase price for each share of Series A preferred stock is $0.01, potentially raising up to $450.00.
• The primary purpose of this offering is to secure stockholder approval for a reverse stock split proposal.
• Each share of Series A preferred stock is convertible into common stock at an initial conversion price of $0.01 per share, contingent upon stockholder approval for the reverse stock split.
• Holders of the Series A preferred stock have agreed to vote on the reverse stock split proposal in the same proportions as the common stockholders.
• The company may compel conversion of the Series A preferred stock after certain conditions are met.
• Holders have the right to require the company to redeem their shares for cash at the stated value commencing after the earlier of stockholder approval of the authorized share increase and 90 days after the closing of the issuance of the Series A preferred stock and until 120 days after such closing.
• Net proceeds from this offering will be used for general corporate purposes if the Series A preferred stock is converted or not redeemed after 120 days from closing.
• The offering is exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.
• The company will hold a special meeting of stockholders on or about March 28, 2025, for the purpose of obtaining the Amendment with the recommendation of the company's Board of Directors that such proposals are approved.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, it's a small amount and primarily for a reverse stock split, which can be viewed as a neutral or slightly negative event. The terms of the offering are fairly standard for a private placement.

Positives

• The capital injection of up to $450.00 provides Ocean Biomedical with funds for general corporate purposes.
• The structure of the Series A preferred stock ensures that the reverse stock split vote aligns with the interests of common stockholders.
• The company may compel conversion of the Series A preferred stock after certain conditions are met.
• The private placement allows the company to raise capital without the complexities of a public offering.

Negatives

• The offering is small, raising only up to $450.00.
• The Series A preferred stock is primarily for voting on the reverse stock split, limiting its use for other corporate matters.
• The company may be forced to redeem the shares for cash at the stated value commencing after the earlier of stockholder approval of the authorized share increase and 90 days after the closing of the issuance of the Series A preferred stock and until 120 days after such closing.

Risks

• Failure to obtain stockholder approval for the reverse stock split could impact the company's plans.
• The redemption feature of the Series A preferred stock could require the company to use cash to redeem the shares.
• The private placement is subject to the risk that the purchasers may not fulfill their obligations.
• The Series A preferred stock and underlying shares of common stock have not been registered under the Act, or applicable state securities laws.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes if the Series A preferred stock is converted or not redeemed after 120 days from closing. The primary focus is on obtaining stockholder approval for the reverse stock split.

Industry Context

Private placements are a common method for small-cap companies to raise capital, particularly when seeking to fund specific initiatives or address immediate financial needs. The use of preferred stock with voting rights tied to a specific proposal (reverse stock split) is a less common but targeted approach.

Comparison to Industry Standards

• The structure of this offering, with preferred stock primarily used for voting on a reverse stock split, is not typical compared to standard private placements.
• Comparable companies often use private placements to fund research and development, clinical trials, or acquisitions, rather than primarily for facilitating corporate actions like reverse stock splits.
• The size of the offering ($450.00) is relatively small compared to typical private placements in the biotechnology sector.

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split.
• The company's financial position will be slightly improved by the capital raise.
• The offering could affect the trading price and volume of the company's stock.

Next Steps

• Hold a special meeting of stockholders on or about March 28, 2025, to vote on the reverse stock split proposal.
• File necessary documents with the SEC and state securities regulators.
• Issue the Series A preferred stock to the purchasers.
• Potentially convert the Series A preferred stock into common stock or redeem the shares for cash.

Key Dates